A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and tolerability of long-term maintenance
therapy with rituximab in participants with advanced follicular lymphoma who have had a
positive response to first-line treatment with a rituximab-containing regimen. The
anticipated time on study treatment is 2 years, and the target sample size is 124
individuals.